Beam Therapeutics
Beam Therapeutics raises $206M Series C at $3.5B valuation
Beam Therapeutics: Series C Funding Round
Beam Therapeutics has successfully raised $206M in Series C funding, reaching a valuation of $3.5B.
Company Overview
Base editing technology
Funding Details
The Series C round was led by Foresite Capital, with participation from F-Prime Capital, Omega Funds, Redmile Group, Wellington Management.
Company Information
- Headquarters: 238 Main Street, Cambridge, MA 02142
- Founded: 2017
- Employees: 400+
- Category: Biotech
Investment
Beam Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- Omega Funds: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Wellington Management: Verified investor in Series C
Company Info
Investors (5)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free